XBIO (Xenetic Biosciences, Inc.) PDUFA Date | FDA Catalyst & Approval Status

Jun 4, 2026

Xenetic Biosciences, Inc. Announces That Its Collaboration Partner Received Approval From the Israeli Ministry of Health to Conduct Exploratory, Investigator Initiated Study of DNase I In Combination With Anti-CD19 CAR T Cells in Large B-Cell Lymphoma

Xenetic Biosciences announced that its partner, PeriNess Ltd., received approval from the Israeli Ministry of Health to conduct an exploratory study combining DNase I with anti-CD19 CAR T cells for large B-cell lymphoma patients. The study aims to evaluate the efficacy of this combination therapy, which has shown promising preclinical results, in improving patient outcomes.

Jun 1, 2026

▲ +5.1%on this newsshared move

Xenetic Biosciences Showcases Compelling ASCO 2026 Data Demonstrating DNase I Significantly Enhances CAR-T Cell Persistence, Tumor Control, and Survival

Xenetic Biosciences presented promising preclinical data at ASCO 2026, demonstrating that DNase I significantly enhances CAR-T cell expansion, persistence, and antitumor efficacy in aggressive hematologic cancers. The findings suggest DNase I could be a valuable adjunct therapy to improve outcomes for patients with difficult-to-treat malignancies. The data supports continued clinical development of DNase I in combination with CAR-T therapies.

Xenetic Biosciences Reports First Quarter 2026 Financial Results and Highlights Continued Advancement of DNase Oncology Platform

Xenetic Biosciences reported its Q1 2026 financial results, highlighting a 36% increase in royalty revenue and significant advancements in its DNase oncology platform. The company ended the quarter with $7.3 million in cash and a reduced net loss of $0.5 million. A collaboration partner received approval for a study combining DNase I with CAR T cells in lymphoma, showcasing the platform's potential.

Apr 23, 2026

Xenetic Biosciences, Inc. Announces Abstract Acceptance for Presentation at the 2026 ASCO Annual Meeting

Xenetic Biosciences, Inc. announced that its abstract has been accepted for presentation at the 2026 ASCO Annual Meeting. The research focuses on a DNase-based therapeutic approach aimed at enhancing CAR T-cell function and improving antitumor responses. The presentation will take place on June 1, 2026, in Chicago, IL.

Mar 13, 2026

▲ +9.5%on this news· ran to +32% by day 1

Xenetic Biosciences, Inc. Reports Full Year 2025 Financial Results

Xenetic Biosciences reported its financial results for 2025, highlighting progress in its DNase-based technology aimed at treating difficult cancers. The company is advancing toward Phase 1 clinical development and has seen increased royalty revenues. However, it also reported a net loss of approximately $2.7 million for the year, reflecting ongoing investments in its scientific programs.

Dec 11, 2025

Xenetic Biosciences, Inc. Announces Adjournment of 2025 Annual Meeting Adjourns 2025 Annual Meeting of Stockholders Urges Stockholders Who Have Not Voted To Get Votes In FRAMINGHAM, MA - (

Xenetic Biosciences, Inc. has announced that its 2025 Annual Meeting of Stockholders was adjourned without any business conducted due to a lack of quorum. The company will reconvene the meeting virtually on January 8, 2026, to allow more time for stockholders to submit their votes. Those who have already submitted their proxies need not vote again, but participation from stockholders who have not yet voted is encouraged to ensure adequate representation.

Nov 13, 2025

Xenetic Biosciences, Inc. Reports Third Quarter 2025 Financial Results Continued execution on collaborations and exploratory investigator-initiated studies with institutional partners Secured net proceeds of approximatel

Xenetic Biosciences, Inc. has reported its financial results for the third quarter of 2025. The company continues to advance its DNase-based program for cancer treatment while securing $3.9 million from a recent capital offering. Despite a net loss of $0.5 million this quarter, increased revenue and successful partnerships provide a positive outlook for its research efforts. The company is now preparing for Phase 1 clinical trials amid a strategic review process that poses some uncertainties.

Oct 10, 2025

▼ -33.1%on this news· ran to -49% by day 3

Xenetic Biosciences, Inc. Announces Pricing of $4.5 Million Underwritten Offering of Common Stock FRAMINGHAM, MA.

Xenetic Biosciences, Inc. has announced the pricing of an underwritten offering of 735,000 shares of common stock at $6.12 per share, aiming to raise approximately $4.5 million. The offering is set to close on or around October 14, 2025, subject to customary closing conditions. The proceeds will be allocated for working capital and general corporate purposes. The biotech firm emphasizes its commitment to improving cancer treatments through its innovative DNase platform.

Xenetic Biosciences, Inc. Reports Second Quarter 2025 Financial Results Expanded strategic partnership with The Scripps Research Institute to advance proof-of-concept studies and further develop its program combining sys

Xenetic Biosciences, Inc. has reported its financial results for Q2 2025, highlighting a significant expansion of its partnership with The Scripps Research Institute. This collaboration aims to advance the program evaluating systemic DNase I combined with CAR T-cell therapies. The company reported a net loss of approximately $0.7 million and reduced research and development costs, showing a focus on efficient operations. With $4.8 million in cash, Xenetic is preparing for Phase 1 clinical trials targeting pancreatic carcinoma and other solid tumors.

May 14, 2025

Xenetic Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides Business Update Strategic focus on exploratory investigator-initiated clinical studies with institutional partners Continued progress of

Xenetic Biosciences, Inc. reported its financial results for the first quarter of 2025, highlighting a revenue increase of 16.1% to approximately $0.6 million. The company continues to advance its DNase I development program towards clinical studies for pancreatic carcinoma and has formed a Clinical Study Agreement with PeriNess Ltd. to develop treatments for certain cancers. Despite a reported net loss of approximately $0.9 million, the company's strategic focus on partnerships aims to enhance its technological advancements in immuno-oncology therapies.

Mar 19, 2025

CONFIDENTIAL DRAFT NOT FOR IMMEDIATE RELEASE Xenetic Biosciences, Inc. Reports Full Year 2024 Financial Results Encouraging preclinical data supporting the use of DNase-based technology to target NETosis and address diff

Xenetic Biosciences, Inc. reported its 2024 financial results, highlighting progress in its DNase-based technology for treating difficult cancers. The company has established collaborations with significant partners to further develop its promising therapies, especially for pancreatic carcinoma. Despite a net loss of $4.0 million, Xenetic aims to push forward towards an IND application and Phase 1 clinical trials in 2025. The decrease in research spending could raise concerns about resource allocation, but the overall outlook remains optimistic due to advancements in preclinical data.

Xenetic Biosciences, Inc. Reports Third Quarter 2024 Financial Results - Establishing growing body of preclinical data evaluating the DNase-based oncology platform across a number of high-value oncology indications - Ong

Xenetic Biosciences, Inc. has reported its financial results for the third quarter of 2024, showcasing advancements in its DNase-based oncology platform. The company is making progress towards its first clinical studies for treating locally advanced and metastatic solid tumors. Financially, Xenetic ended the quarter with $6.8 million in cash, but also faced a net loss and reduced R&D expenditures relative to the previous year. Additionally, the company highlighted its partnerships with prestigious institutions to enhance its development strategy.

Xenetic Biosciences, Inc. Extends Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform Company is advancing DNase-based oncology program towards clinical proof-of-concept s

Xenetic Biosciences, Inc. announced an extension of its research collaboration with The Scripps Research Institute to advance its DNase-based oncology program. This program will focus on combining systemic DNase with CAR T-cell therapies to improve treatment outcomes for cancers such as pancreatic carcinoma. Preclinical studies indicate that DNase I can reduce tumor burden and enhance the effectiveness of CAR-T treatments by targeting neutrophil extracellular traps in the tumor microenvironment. The collaboration aims to move towards clinical proof-of-concept studies, demonstrating the potential of this innovative approach in complex cancer indications.

Xenetic Biosciences, Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update - Ongoing preclinical studies with data expected before year end - Focus on demonstration of DNase-based oncology progr

Xenetic Biosciences, Inc. reported its financial results for the second quarter of 2024, highlighting a net loss of $1.3 million. The company emphasized its commitment to advancing its DNase-based oncology platform, with preclinical data anticipated before the end of the year. Ongoing efforts are focused on moving towards first-in-human clinical studies for treatments targeting hard-to-treat cancers, particularly pancreatic carcinoma. Despite some increases in operational costs, Xenetic remains optimistic about its pipeline and innovation potential.

Xenetic Biosciences, Inc. Announces Executive Leadership Transition Company's Board of Directors Appoint James F. Parslow to Interim Chief Executive Officer FRAMINGHAM, MA - (

Xenetic Biosciences, Inc. announced the appointment of James F. Parslow as the interim Chief Executive Officer, effective May 16, 2024. Mr. Parslow, previously Chief Financial Officer, aims to drive the company's resources toward clinical studies for its DNase-based oncology program. The company focuses on treatments for hard-to-treat cancers, including pancreatic carcinoma. This leadership transition comes with the commitment to extend cash runway and continue advancing their pipeline.

May 10, 2024

Xenetic Biosciences, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update - Ongoing preclinical studies with multiple data readouts expected throughout remainder of 2024 - Continued advancement

Xenetic Biosciences, Inc. reported its financial results for the first quarter of 2024, revealing a net loss of approximately $1.2 million. The company is advancing its DNase platform, with promising preclinical studies set to provide data in the latter half of the year. CEO Jeffrey Eisenberg expressed optimism about the potential impact these studies may have on treatment strategies for certain solid tumors. Despite the losses, the company ended the quarter with approximately $7.8 million in cash, supporting its ongoing development efforts.

Mar 22, 2024

Xenetic Biosciences, Inc. Reports Full Year 2023 Financial Results Continued advancement of DNase-based oncology program towards Phase 1 clinical study for the treatment of pancreatic carcinoma and other locally advanced

Xenetic Biosciences, Inc. reported its financial outcomes for the year ended December 31, 2023, highlighting advancements in its DNase-based oncology program aimed at treating pancreatic carcinoma. The company is poised to initiate a Phase 1 clinical trial based on encouraging preclinical data. Financially, Xenetic faced a net loss of $4.1 million, despite a notable increase in royalty payments from Takeda Pharmaceuticals. The firm is navigating financial challenges while aiming to realize the full potential of its DNase platform and other treatments for hard-to-treat cancers.

Nov 10, 2023

Xenetic Biosciences, Inc. Reports Third Quarter 2023 Financial Results - Encouraging growing body of preclinical data guiding pathway to first in human trial for DNase-based oncology platform - Driving development toward

Xenetic Biosciences, Inc. announced its third quarter 2023 financial results, highlighting a promising trajectory for its DNase-based oncology platform with encouraging preclinical data. The company is preparing for its first-in-human trials aimed at treating pancreatic carcinoma amidst ongoing financial investments in research and development. Despite a reported net loss of $1.1 million in the quarter, Xenetic noted a notable increase in royalty payments from its alliance with Takeda Pharmaceuticals. The company is also looking to enhance its development capabilities through strategic partnerships.

Aug 11, 2023

Xenetic Biosciences, Inc. Reports Second Quarter 2023 Financial Results - Company continues to execute on plan to advance DNase-based oncology program towards Phase 1 clinical development for the treatment of pancreatic

Xenetic Biosciences, Inc. reported its financial results for the second quarter of 2023, highlighting progress in its DNase-based oncology program aimed at treating pancreatic carcinoma. The company has taken significant steps, including securing collaborations and expanding its team, as it prepares for Phase 1 clinical development. Despite reporting a net loss of $1.1 million this quarter, R&D expenses have decreased significantly from the previous year. The financial outlook appears stable with an end-of-quarter cash balance of approximately $10.7 million and no debt.

Jun 6, 2023

nasdaq : XBIO xeneticbio.com Corporate Presentation June 2023 This presentation contains forward - looking statements that we intend to be subject to the safe harbor provisions of the Private Securities Litigation Reform

Xenetic Biosciences (XBIO) presented an update on its corporate strategy focusing on the DNase I technology platform aimed at enhancing oncology treatments. The platform targets Neutrophil Extracellular Traps (NETs), which hinder the effectiveness of existing therapies. Upcoming studies are set to evaluate its combination with chemotherapy and immune checkpoint inhibitors to improve patient outcomes. However, the company acknowledges potential risks, including financial uncertainties and challenges in realizing the full potential of its technology.

May 12, 2023

▼ -17.5%on this news· ran to -28% by day 3

Xenetic Biosciences, Inc. Announces Reverse Stock Split of Common Stock FRAMINGHAM, MA - (

Xenetic Biosciences, Inc. announced a one-for-ten reverse stock split effective on May 15, 2023. This move aims to reorganize its authorized, issued, and outstanding common stock on the Nasdaq Capital Market under the ticker XBIO. The company is focused on developing immune-oncology technologies that address challenging cancers, particularly through its DNase platform. Despite the potential benefits, the announcement comes with inherent uncertainty regarding the company's future performance.

May 11, 2023

Xenetic Biosciences, Inc. Reports First Quarter 2023 Financial Results and Provides Business Update - Continued progress with the DNase-based oncology program towards Phase 1 study for the treatment of pancreatic carcino

Xenetic Biosciences, Inc. announced its financial results for Q1 2023, highlighting advancements in its DNase-based oncology program aimed at treating pancreatic carcinoma and other tumors. The company reported a net loss of approximately $0.9 million and a significant cash reserve of $12 million to support ongoing operations. Additionally, Xenetic established a collaboration with The Scripps Research Institute to further its systemic DNase program. Royalty income from a sublicense with Takeda Pharmaceuticals also saw a positive increase.

Mar 23, 2023

Xenetic Biosciences, Inc. Reports Full Year 2022 Financial Results and Provides Business Update - Year marked by transformational strategic license of the DNase oncology platform and shift in focus to treatment of locall

Xenetic Biosciences, Inc. reported its financial results for the full year 2022, highlighting a transformational year marked by the strategic licensing of its DNase oncology platform. The company is progressing towards a Phase 1 clinical trial for its DNase program aimed at treating locally advanced or metastatic solid tumors. Financially, Xenetic ended the year with $13.1 million in cash, but reported a net loss of approximately $6.6 million. The company has appointed experts to its Scientific Advisory Board to advance the development of its platforms, amid efforts to strengthen its oncology pipeline.

Nov 10, 2022

Xenetic Biosciences, Inc. Reports Third Quarter 2022 Financial Results and Provides Business Update - Continued advancement of lead technology, DNase-based oncology platform, in locally advanced or metastatic solid tumor

Xenetic Biosciences, Inc. Reports Third Quarter 2022 Financial Results and Provides Business Update - Continued advancement of lead technology, DNase-based oncology platform, in locally advanced or metastatic solid tumors towards Phase 1 clinical development - Ended the quart

Aug 12, 2022

Xenetic Biosciences, Inc. Reports Second Quarter 2022 Financial Results and Provides Business Update - Second quarter marked by deal to in-license DNase-based oncology platform which expands pipeline with well-defined an

Xenetic Biosciences, Inc. Reports Second Quarter 2022 Financial Results and Provides Business Update - Second quarter marked by deal to in-license DNase-based oncology platform which expands pipeline with well-defined and accelerated path to clinic - Advancing lead DNase prog

Jul 7, 2022

▲ +6.6%on this news· ran to +17% by day 3

Xenetic Biosciences, Inc. Engages Catalent for Clinical Manufacturing to Advance DNase-Based Oncology Platform Towards Phase 1 Study - DNase-based oncology platform has the potential to improve outcomes of existing thera

Xenetic Biosciences, Inc. Engages Catalent for Clinical Manufacturing to Advance DNase-Based Oncology Platform Towards Phase 1 Study - DNase-based oncology platform has the potential to improve outcomes of existing therapeutic agents in multiple solid tumor indications - Syst

Apr 27, 2022

▼ -7.8%on this news· ran to -20% by day 3

Xenetic Biosciences, Inc. Expands Oncology Pipeline with In-Licensing of DNase Based Oncology Platform Comprising Multiple Therapeutic Modalities Transaction with CLS Therapeutics for DNase platform includes two pre-clin

Xenetic Biosciences, Inc. Expands Oncology Pipeline with In-Licensing of DNase Based Oncology Platform Comprising Multiple Therapeutic Modalities Transaction with CLS Therapeutics for DNase platform includes two pre-clinical development programs and creates near-term clinical

Mar 23, 2022

Xenetic Biosciences, Inc. Reports Full Year 2021 Financial Results and Provides Business Update - XCART TM continuing to advance toward IND-enabling studies - PolyXen platform technology growing royalty stream through li

Xenetic Biosciences, Inc. Reports Full Year 2021 Financial Results and Provides Business Update - XCARTTM continuing to advance toward IND-enabling studies - PolyXen platform technology growing royalty stream through license agreement - Closed the year with $18.2 million of

Nov 12, 2021

Xenetic Biosciences, Inc. Reports Third Quarter 2021 Financial Results and Provides Business Update - Company advancing XCART TM pre-clinical development plan toward IND-enabling studies - Strengthened cash position to f

Xenetic Biosciences, Inc. Reports Third Quarter 2021 Financial Results and Provides Business Update - Company advancing XCARTTM pre-clinical development plan toward IND-enabling studies - Strengthened cash position to fund operations through XCART IND filing with recently co

Sep 13, 2021

Expanding the Potential of CAR T CellTherapy NASDAQ:XBIO xeneticbio.com InvestorPresentation September 2021 Forward-LookingStatements Thispresentationcontainsforward-lookingstatementsthatweintendtobesubjecttothesafeharbo

Expanding the Potential of CAR T CellTherapy NASDAQ:XBIO xeneticbio.com InvestorPresentation September 2021 Forward-LookingStatements Thispresentationcontainsforward-lookingstatementsthatweintendtobesubjecttothesafeharborprovisionsofthePrivateSecuritiesLitigationReform Act of199

Xenetic Biosciences, Inc. Reports Second Quarter 2021 Financial Results and Provides Business Update - Continued execution on XCART pre-clinical development plan and progress toward IND-enabling studies - Strong royalty

Xenetic Biosciences, Inc. Reports Second Quarter 2021 Financial Results and Provides Business Update - Continued execution on XCART pre-clinical development plan and progress toward IND-enabling studies - Strong royalty growth with PolyXen - Bolstered cash position with rece

Jul 28, 2021

Xenetic Biosciences, Inc. Announces Closing of $12.5 Million Private Placement Priced at a Premium to Market FRAMINGHAM, MA / ACCESSWIRE /

Xenetic Biosciences, Inc. Announces Closing of $12.5 Million Private Placement Priced at a Premium to Market / ACCESSWIRE / July 28, 2021 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing XCART , a personal

May 12, 2021

Xenetic Biosciences, Inc. Reports First Quarter 2021 Financial Results - Continued execution on XCART development plan with commencement of exploratory patient biopsy trial expected to position the Company to conduct IND

Xenetic Biosciences, Inc. Reports First Quarter 2021 Financial Results - Continued execution on XCART development plan with commencement of exploratory patient biopsy trial expected to position the Company to conduct IND-enabling studies in the United States - Licensing part

Mar 17, 2021

Xenetic Biosciences, Inc. Reports Fourth Quarter and Full Year 2020 Financial Results - Driving development of XCART platform and leveraging academic collaborations through preclinical development - Recent clinical, regu

Xenetic Biosciences, Inc. Reports Fourth Quarter and Full Year 2020 Financial Results - Driving development of XCART platform and leveraging academic collaborations through preclinical development - Recent clinical, regulatory and commercial advancements from licensing partne

Jan 19, 2021

Expanding the Potential of CAR T Cell Therapy NASDAQ: XBIO xeneticbio.com 2021 Investor Presentation JANUARY Forward - Looking Statements This presentation contains forward - looking statements for purposes of the safe h

Expanding the Potential of CAR T Cell Therapy NASDAQ: XBIO xeneticbio.com 2021 Investor Presentation JANUARY Forward - Looking Statements This presentation contains forward - looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Refor

Dec 10, 2020

Xenetic Biosciences, Inc. Announces $6.0 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules FRAMINGHAM, MA - (

Biosciences, Inc. Announces $6.0 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules MA - (December 10, 2020) - Xenetic Biosciences, Inc. (NASDAQ: XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing XCART , a personalized

Nov 13, 2020

Xenetic Biosciences, Inc. Reports Third Quarter 2020 Financial Results and Provides Corporate Update - Continued advancement of XCART platform towards an IND filing and Phase 1 Study - Leveraging partnerships with leadin

Biosciences, Inc. Reports Third Quarter 2020 Financial Results and Provides Corporate Update Continued advancement of XCART platform towards an IND filing and Phase 1 Study Leveraging partnerships with leading global academic institutions, including Scripps Research MA - (Nove

Aug 13, 2020

Xenetic Biosciences, Inc. Reports Second Quarter 2020 Financial Results and Provides Corporate Update - Successfully established two strategic academic collaborations in Q2 2020 to advance development of XCART , its diff

Biosciences, Inc. Reports Second Quarter 2020 Financial Results and Provides Corporate Update Successfully established two strategic academic collaborations in Q2 2020 to advance development of XCART , its differentiated CAR T therapy platform - Strengthened panel of experts o

Jun 16, 2020

Xenetic Biosciences, Inc. Announces Collaboration with Pharmsynthez and Multiple Academic Institutions in Russia and Belarus to Advance Development of XCART Platform Goal of XCART collaboration to optimize XCART process,

Xenetic Biosciences, Inc. Announces Collaboration with Pharmsynthez and Multiple Academic Institutions in Russia and Belarus to Advance Development of XCART Platform o Shemyakin and Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences ( IBCh RAS )

May 19, 2020

Xenetic Biosciences, Inc. Announces Research and Development Collaboration with Scripps Research to Advance XCART Platform - Represents significant milestone in strategic development plan to advance XCART through academi

Biosciences, Inc. Announces Research and Development Collaboration with Scripps Research to Advance XCART Platform Represents significant milestone in strategic development plan to advance XCART through academic collaborations - Provides access to leading research institution w

May 14, 2020

Xenetic Biosciences, Inc. Reports First Quarter 2020 Financial Results and Provides Corporate Update - Company poised to execute on near- and long-term value-driving milestones to advance preclinical development of its X

Biosciences, Inc. Reports First Quarter 2020 Financial Results and Provides Corporate Update Company poised to execute on near- and long-term value-driving milestones to advance preclinical development of its XCART CAR T therapy platform - Continuing to progress discussions to

Mar 27, 2020

Xenetic Biosciences, Inc. Reports 2019 Year End Results and Provides Corporate Update - Company continues to advance preclinical development of its XCART CAR T therapy platform - - Expands XCART resources by adding exper

Xenetic Biosciences, Inc. Reports 2019 Year End Results and Provides Corporate Update Company continues to advance preclinical development of its XCART CAR T therapy platform - Expands XCART resources by adding expertise in cell therapy translational science and CMC - Cash on

Nov 15, 2019

Xenetic Biosciences, Inc. Reports Third Quarter 2019 Financial Results and Provides Corporate Update - Company ramps up activities to execute XCART's preclinical and regulatory strategy - - Cash runway expected to fund C

Xenetic Biosciences, Inc. Reports Third Quarter 2019 Financial Results and Provides Corporate Update Company ramps up activities to execute XCART's preclinical and regulatory strategy - Cash runway expected to fund Company through preclinical advancements towards IND filing -

Oct 8, 2019

Xenetic Biosciences, Inc. Provides Business Outlook - Recent completion of acquisition of innovative CAR T technology platform (XCART) has the potential to drive significant value for shareholders - - Management working

Xenetic Biosciences, Inc. Provides Business Recent completion of acquisition of innovative CAR T technology platform (XCART) has the potential to drive significant value Management working with KOLs and subject matter experts to formalize XCART development plan - Completion of

Sep 9, 2019

Enhancing lives with transformative therapies www.xeneticbio.com NASDAQ: XBIO Corporate Presentation September 2019 Forward - Looking Statements This presentation contains forward - looking statements for purposes of the

Enhancing lives with transformative therapies www.xeneticbio.com NASDAQ: XBIO Corporate Presentation September 2019 Forward - Looking Statements This presentation contains forward - looking statements for purposes of the safe harbor provisions of the Private Securities Litigatio

Aug 15, 2019

Xenetic Biosciences, Inc. Reports Second Quarter 2019 Financial Results and Provides Corporate Update - Building momentum with recent acquisition of innovative XCART platform technology and closing of $15 million underwr

Biosciences, Inc. Reports Second Quarter 2019 Financial Results and Provides Corporate Update Building momentum with recent acquisition of innovative XCART platform technology and closing of $15 million underwritten public Corporate strategy shift with entry into the CAR T spac

Jul 22, 2019

Xenetic Biosciences, Inc. Closes $15.0 Million Underwritten Public Offering and Completes Acquisition of Innovative CAR T Technology Platform - Innovative XCART technology platform designed to target personalized, patien

Biosciences, Inc. Closes $15.0 Million Underwritten Public Offering and Acquisition of Innovative CAR T Technology Platform Innovative XCART technology platform designed to target personalized, patient-specific tumor neoantigens has the potential to transform XCART expected to

Jul 17, 2019

Xenetic Biosciences, Inc. (Nasdaq: XBIO) Announces Pricing of $15.0 Million Underwritten Public Offering FRAMINGHAM, MA - (

Xenetic Biosciences, Inc. (Nasdaq: XBIO) Announces Pricing of $15.0 Million Underwritten Public Offering FRAMINGHAM, MA - (July 17, 2019) - Xenetic Biosciences, Inc. (NASDAQ: XBIO) ("Xenetic" or the "Company"), a clinical-stage biopharmaceutical company focused on the discove

May 13, 2019

Xenetic Biosciences, Inc. Reports First Quarter 2019 Financial Results and Provides Corporate Update - Company on track to close acquisition of novel XCART platform technology - Entry into CAR T space positions company t

Xenetic Biosciences, Inc. Reports First Quarter 2019 Financial Results and Provides Corporate Update Company on track to close acquisition of novel XCART platform technology Entry into CAR T space positions company to drive significant momentum over the course of 2019 advancin

Mar 5, 2019

Xenetic Biosciences Announces Pricing of $3.1 Million Registered Direct Offering

Biosciences Announces Pricing of $3.1 Million Registered Direct Offering Mass.-March 5, 2019 -- Xenetic Biosciences, Inc. (NASDAQ: XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on the acquisition, research and development of novel oncology therapeutics

Mar 4, 2019

Xenetic Biosciences, Inc. (NASDAQ: XBIO) Announces Agreement to Acquire Innovative CAR T Technology Platform - Innovative XCART platform with demonstrated proof of mechanism and preclinical evidence of target specificity

Biosciences, Inc. (NASDAQ: XBIO) Announces Agreement to Acquire Innovative CAR T Technology Platform Innovative XCART platform with demonstrated proof of mechanism and preclinical evidence of target specificity positions Xenetic to address high value oncology market with differ

Nov 15, 2017

Xenetic Biosciences Reports 2017 Third Quarter Financial Results and Provides Corporate Update LEXINGTON, MA - (

Xenetic Biosciences Reports 2017 Third Quarter Financial Results and Provides Corporate Update MA - (November 15, 2017) - Xenetic Biosciences, Inc. (NASDAQ: XBIO) ("Xenetic" or the "Company"), a clinical-stage biopharmaceutical company focused on the discovery, research and d

Nov 2, 2017

Xenetic Biosciences Enters Into Sublicense Agreement Related to its PolyXen Technology with Baxalta Inc., a Wholly-owned Subsidiary of Shire plc - Xenetic to receive one-time payment of $7.5M and single digit royalty pay

Xenetic Biosciences Enters Into Sublicense Agreement Related to its PolyXen Technology with Baxalta Inc., a Wholly-owned Subsidiary of Shire plc - Xenetic to receive one-time payment of $7.5M and single digit royalty payments based upon net sales - MA - (November 2, 2017) - X

Oct 31, 2017

Xenetic Biosciences Appoints Jeffrey F. Eisenberg as Chief Executive Officer LEXINGTON, MA - (

Xenetic Biosciences Appoints Jeffrey F. Eisenberg as Chief Executive Officer MA - (October 31, 2017) - Xenetic Biosciences, Inc. (NASDAQ: XBIO) ("Xenetic" or the "Company"), a clinical-stage biopharmaceutical company focused on the discovery, research and development of next-

Aug 15, 2017

Xenetic Biosciences Reports 2017 Second Quarter Financial Results and Provides Business Update LEXINGTON, MA - (

Xenetic Biosciences Reports 2017 Second Quarter Financial Results and Provides Business Update MA - (August 15, 2017) - Xenetic Biosciences, Inc. (NASDAQ: XBIO) ("Xenetic" or the "Company"), a clinical-stage biopharmaceutical company focused on the discovery, research and dev

Aug 14, 2017

Xenetic Biosciences Announces Appointment of Three Directors to the Board New Board appointments add drug development, operational and strategic financial expertise LEXINGTON, MA - (

Xenetic Biosciences Announces Appointment of Three Directors to the Board New Board appointments add drug development, operational and strategic financial expertise MA - (August 14, 2017) - Xenetic Biosciences, Inc. (NASDAQ: XBIO) ("Xenetic" or the "Company"), a clinical-sta

May 22, 2017

Xenetic Biosciences Receives Program Update from Partner Shire's Phase 1/2 Study Evaluating SHP656 in Development as a Long-acting Treatment for Hemophilia A - SHP656 program utilizes Xenetic's PolyXen platform technolog

Biosciences Receives Program Update from Partner Shire's Phase 1/2 Study Evaluating SHP656 in Development as a Long-acting Treatment for Hemophilia A - SHP656 program utilizes Xenetic's PolyXen platform technology to conjugate polysialic acid to therapeutic blood-clotting fact

Apr 4, 2017

Xenetic Biosciences Expands Executive Management Team with Appointment of James F. Parslow, MBA, CPA as Chief Financial Officer LEXINGTON, MA - (

Xenetic Biosciences Expands Executive Management Team with Appointment of James F. Parslow, MBA, CPA as Chief Financial MA - (April 4, 2017) - Xenetic Biosciences, Inc. (NASDAQ: XBIO) ("Xenetic" or the "Company"), a clinical-stage biopharmaceutical company focused on the disc

Mar 29, 2017

Xenetic Biosciences, Inc. (Nasdaq: XBIO) to Ring The Nasdaq Stock Market Opening Bell

ADVISORY, March 29, 2017 (GLOBE NEWSWIRE) -- Xenetic Biosciences, Inc. (Nasdaq:XBIO), a clinical-stage biopharmaceutical company focused on the discovery, research and development of next-generation biologic drugs and novel orphan oncology therapeutics, will visit the Nasdaq Mar

Jan 4, 2017

Xenetic Biosciences Appoints Curtis A. Lockshin, Ph.D. as Chief Scientific Officer LEXINGTON, MA - (

Xenetic Biosciences Appoints Curtis A. Lockshin, Ph.D. as Chief Scientific Officer MA - (January 4, 2017) - Xenetic Biosciences, Inc. (NASDAQ: XBIO) ("Xenetic" or the "Company"), a clinical-stage biopharmaceutical company focused on the discovery, research and development of

Dec 5, 2016

Xenetic Biosciences Expands Management Team with Key Appointment of Jeffrey F. Eisenberg as Chief Operating Officer LEXINGTON, MA - (

Xenetic Biosciences Expands Management Team with Key Appointment of Jeffrey F. Eisenberg as Chief Operating Officer MA - (December 5, 2016) - Xenetic Biosciences, Inc. (NASDAQ: XBIO) ("Xenetic" or the "Company"), a clinical-stage biopharmaceutical company focused on the disc

Nov 22, 2016

Xenetic Biosciences Appoints Edward J. Benz, Jr., M.D., Former Dana-Farber CEO, to its Board of Directors LEXINGTON, MA - (

Xenetic Biosciences Appoints Edward J. Benz, Jr., M.D., Former Dana-Farber CEO, to its Board of Directors MA - (November 22, 2016) - Xenetic Biosciences, Inc. (NASDAQ: XBIO) ("Xenetic" or the "Company"), a clinical-stage biopharmaceutical company focused on the discovery, re

Jul 11, 2016

Xenetic Biosciences Appoints Jeffrey F. Eisenberg to the Board of Directors LEXINGTON, MA - (

Biosciences Appoints Jeffrey F. Eisenberg to the Board of Directors MA - (July 11, 2016) - Xenetic Biosciences, Inc. (OTCQB: XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company developing next-generation biologic drugs and novel orphan oncology therapeutics, today

Jun 1, 2016

Xenetic Biosciences Announces Reverse Stock Split in Preparation for Proposed Uplisting to Nasdaq Capital Market LEXINGTON, MA - (

Biosciences Announces Reverse Stock Split in Preparation for Proposed Uplisting to Nasdaq Capital Market MA - (June 1, 2016) - Xenetic Biosciences, Inc. (OTCQB: XBIO) ("Xenetic" or "the Company"), a biopharmaceutical company developing next-generation biologic drugs and novel o

Feb 29, 2016

Xenetic Biosciences Appoints Renowned Chemist and Nobel Laureate, Dr. Roger D. Kornberg, to Board of Directors

Biosciences Appoints Renowned Chemist and Nobel Laureate, Dr. Roger D. Kornberg, to Board of Directors Mass., Feb 29, 2016 -- Xenetic Biosciences, Inc. (OTCQB: XBIO), a biopharmaceutical company developing next-generation biologic drugs and novel oncology therapeutics, today an

Nov 16, 2015

Xenetic Biosciences, Inc. Enters Into Asset Purchase Agreement With Financing Component for the Rights to Develop, Market and License Oncologic Drug Candidate Virexxa™

LEXINGTON, Mass., Nov. 16, 2015 (GLOBE NEWSWIRE) -- Xenetic Biosciences, Inc. (OTCQB:XBIO) (the “Company”), a biopharmaceutical company focused on developing next-generation biologic drugs and novel oncology therapeutics, announces that it has entered into an Asset Purchase Agree

Oct 7, 2015

Xenetic Biosciences, Inc.'s Major Strategic Shareholders Enter Into Long Term Lock-Up Agreements

LEXINGTON, Mass., Oct. 07, 2015 (GLOBE NEWSWIRE) -- Xenetic Biosciences, Inc. (OTCQB:XBIO) (the “Company”), a biopharmaceutical company focused on developing next-generation biologic drugs and novel oncology therapeutics, announces that several of its major shareholders including

Sep 16, 2015

Xenetic Biosciences Commences Third Cohort of Phase 2 Trials on Drug Candidate ErepoXen(R) for Anemia

Trial expands into South Africa Compound uses Patented PolyXen® Technology for Recombinant Erythropoietin LEXINGTON, Mass., Sept. 16, 2015 (GLOBE NEWSWIRE) -- Xenetic Biosciences, Inc. (OTCQB:XBIO), a biopharmaceutical company focused on developing next-generation biologic drug

Sep 9, 2015

Xenetic Biosciences (XBIO) Contracts With Baxter International Inc Have Been Assigned to Baxalta Incorporated Following the Company Spin Out

LEXINGTON, Mass., Sept. 09, 2015 (GLOBE NEWSWIRE) -- Xenetic Biosciences, Inc. (OTCQB:XBIO), a biopharmaceutical company focused on developing next-generation biologic drugs and novel oncology therapeutics, announces that its contracts and arrangements with Baxter Healthcare SA (

Sep 2, 2015

Xenetic Biosciences, Inc. Launches Digital Corporate Communication Channels

LEXINGTON, Mass., Sept. 02, 2015 (GLOBE NEWSWIRE) -- Xenetic Biosciences, Inc. (OTCQB:XBIO), a biopharmaceutical company focused on developing next-generation biologic drugs and novel oncology therapeutics, announces today a suite of online corporate communication channels to mai

Jul 14, 2015

Xenetic Biosciences Reports Phase 2 Data on Drug Candidate ErepoXen(R) for Anemia

Hemoglobin Levels Rose and were Maintained in Therapeutic Range ErepoXen was Generally Well Tolerated With No Significant Treatment-related Adverse Events Compound uses Patented PolyXen® Technology for Recombinant Erythropoietin LEXINGTON, Mass., July 14, 2015 (GLOBE NEWSWIRE)

Jul 8, 2015

Xenetic Biosciences Completes $3,000,000 Bridge Note Financing

LEXINGTON, Mass., July 08, 2015 (GLOBE NEWSWIRE) -- Xenetic Biosciences, Inc. (“Xenetic” or the “Company”) (OTCQB:XBIO), a biopharmaceutical company focused on developing next-generation biologic drugs and novel orphan oncology therapeutics, today announced that it has completed

Apr 21, 2015

Xenetic Biosciences Announces Board Change

LEXINGTON, Mass., April 21, 2015 (GLOBE NEWSWIRE) -- Xenetic Biosciences, Inc. (OTCBB:XBIO), a biopharmaceutical company focused on developing next-generation biologic drugs and novel oncology therapeutics, announces the resignation of Chairman Mark Leuchtenberger. CEO of Xeneti

Jun 30, 2014

Xenetic Biosciences Announces Ongoing Safety Data From Phase 2 Trial of ErepoXen(R)

LEXINGTON, Mass., June 30, 2014 (GLOBE NEWSWIRE) -- Xenetic Biosciences, Inc. (OTCBB:XBIO), a biopharmaceutical company focused on developing next-generation biologic drugs and novel oncology therapeutics, today announced results from its ongoing data analysis of the first cohort

Jun 11, 2014

Xenetic Biosciences Announces Dosing of First Patient on Dialysis in Phase 2a Clinical Study of ErepoXen(R)

LEXINGTON, Mass., June 11, 2014 (GLOBE NEWSWIRE) -- Xenetic Biosciences, Inc. (OTCBB:XBIO), a biopharmaceutical company focused on developing next-generation biologic drugs and novel oncology therapeutics, announced today that its partner, the Serum Institute of India, has dosed

Jun 9, 2014

Xenetic Biosciences Strengthens Technology Patent Portfolio

LEXINGTON, Mass., June 9, 2014 (GLOBE NEWSWIRE) -- Xenetic Biosciences, Inc. (OTCBB:XBIO), a biopharmaceutical company focused on developing next-generation biologic drugs and novel oncology therapeutics, today announced that the U.S. Patent and Trademark Office has granted U.S.

May 29, 2014

Xenetic Biosciences to Present at the Third Annual Marcum MicroCap Conference

LEXINGTON, Mass., May 29, 2014 (GLOBE NEWSWIRE) -- Xenetic Biosciences (OTCBB:XBIO), a biopharmaceutical company focused on developing next-generation biologic drugs and novel oncology therapeutics, announced today that the Company will be a featured presenter at the 3rd Annual M

May 21, 2014

Xenetic Biosciences Announces First Quarter 2014 Financial Results and Business Update

LEXINGTON, Mass., May 21, 2014 (GLOBE NEWSWIRE) -- Xenetic Biosciences (OTCBB:XBIO), a biopharmaceutical company focused on developing next-generation biologic drugs and novel oncology therapeutics, today reported financial results for the quarter ended March 31, 2014. Scott Mag

May 12, 2014

Xenetic Biosciences Announces Positive Phase 1 Clinical Results for PSA-Oxyntomodulin for the Treatment of Type II Diabetes and Obesity

LEXINGTON, Mass., May 12, 2014 (GLOBE NEWSWIRE) -- Xenetic Biosciences, Inc. (OTCBB:XBIO), a biopharmaceutical company focused on developing next-generation biologic drugs and novel oncology therapeutics, today announced positive results from a Phase 1 clinical trial of PSA-Oxynt

May 5, 2014

Xenetic Biosciences Appoints Industry Veteran Mark Leuchtenberger as Chairman of the Board of Directors

LEXINGTON, Mass., May 5, 2014 (GLOBE NEWSWIRE) -- Xenetic Biosciences, Inc. (OTCBB:XBIO), a biopharmaceutical company developing next-generation biologic drugs and novel oncology therapeutics, today announced the appointment of Mark Leuchtenberger as Non-Executive Chairman of the

Apr 16, 2014

Xenetic Biosciences Announces Full Year 2013 Financial Results and Business Update

LEXINGTON, Mass., April 16, 2014 (GLOBE NEWSWIRE) -- Xenetic BioSciences (OTCBB:XBIO), a biopharmaceutical company focused on developing next-generation biologic drugs and novel orphan oncology therapeutics, today reported financial results for the year-ended December 31, 2013.

Apr 7, 2014

Xenetic Biosciences Announces Positive Phase 1 Clinical Data for PulmoXen(TM) for Treatment of Cystic Fibrosis

LEXINGTON, Mass., April 7, 2014 (GLOBE NEWSWIRE) -- Xenetic Biosciences, Inc. (OTCBB:XBIO), a biopharmaceutical company focused on developing next-generation biologic drugs and novel oncology therapeutics, today announced the positive results from its Phase I clinical trial of Pu

Apr 4, 2014

Xenetic Biosciences Appoints Darlene Deptula-Hicks to Board of Directors

LEXINGTON, Mass., April 4, 2014 (GLOBE NEWSWIRE) -- Xenetic Biosciences, Inc. (OTCBB:XBIO), a biopharmaceutical company developing next-generation biologic drugs and novel oncology therapeutics, today announced the appointment of Darlene Deptula-Hicks to its Board of Directors.

Mar 4, 2014

Xenetic Biosciences Announces Opening of Corporate Headquarters and R&D Facility in Lexington, MA

LEXINGTON, Mass., March 4, 2014 (GLOBE NEWSWIRE) -- Xenetic Biosciences, Inc. (OTCBB:XBIO), a biopharmaceutical company focused on developing next-generation biologic drugs and novel oncology therapeutics, today announced the opening of its new corporate headquarters and research

Feb 14, 2014

Xenetic Biosciences Announces Ticker Symbol Change to XBIO

LEXINGTON, Mass., Feb. 14, 2014 (GLOBE NEWSWIRE) -- Xenetic Biosciences, Inc. (OTCBB:XBIO), a biopharmaceutical company focused on developing next-generation biologic drugs and novel oncology therapeutics, today announced that its common stock has commenced trading under new tick

Feb 10, 2014

XBIOFDA Updates

Xenetic Biosciences Appoints Timothy Cot , MD, MPH, Former Head of FDA Orphan Drug Division, to Board of Directors Professor Gregory Gregoriadis, PhD, DSc to retire from Xenetic Biosciences UK subsidiary after 16 years o

Xenetic Biosciences Appoints Timothy Cot , MD, MPH, Former Head of FDA Orphan Drug Division, to Board of Directors Professor Gregory Gregoriadis, PhD, DSc to retire from Xenetic Biosciences UK subsidiary after 16 years of service LEXINGTON, MA: February 10, 2014: Xenetic Bios

Feb 10, 2014

XBIOFDA Updates

Xenetic Biosciences Appoints Timothy Cote, MD, MPH, Former Head of FDA Orphan Drug Division, to Board of Directors

LEXINGTON, Mass., Feb. 10, 2014 (GLOBE NEWSWIRE) -- Xenetic Biosciences, Inc. (OTCBB:GAIFD), a biopharmaceutical company developing next-generation biologic drugs and novel oncology therapeutics, today announced the appointment of Timothy Cot , MD, MPH, to the company's Board of

Jan 30, 2014